Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR

2013 ◽  
Vol 46 (1) ◽  
pp. 39-44 ◽  
Author(s):  
Claudia L Kleinman ◽  
Noha Gerges ◽  
Simon Papillon-Cavanagh ◽  
Patrick Sin-Chan ◽  
Albena Pramatarova ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Microrna Cluster ◽  
Embryonal Brain ◽  
Embryonal Brain Tumor

scholarly journals PNR-17HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANT TO DELAY RADIATION IN PEDIATRIC EMBRYONAL BRAIN TUMOR PATIENTS

2016 ◽  
Vol 18 (suppl 3) ◽  
pp. iii10.1-iii10
Author(s):  
David Raleigh ◽  
Brian Tomlin ◽  
Benedict Del Buono ◽  
Erika Roddy ◽  
Katherine Sear ◽  
...  
Keyword(s):  
Stem Cell ◽  
Brain Tumor ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Tumor Patients ◽  
Embryonal Brain ◽  
Embryonal Brain Tumor

Embryonal brain tumor with unknown primary lesion and massive cerebrospinal fluid dissemination: A case report

2018 ◽  
Vol 54 ◽  
pp. 125-128 ◽  
Author(s):  
Hirotomo Tanaka ◽  
Daisuke Yamamoto ◽  
Mitsuru Ikeda ◽  
Masashi Morikawa ◽  
Kayo Ueda ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumor ◽  
Case Report ◽  
Primary Lesion ◽  
Unknown Primary ◽  
Embryonal Brain ◽  
Embryonal Brain Tumor

scholarly journals Epigenetic regulators Rbbp4 and Hdac1 are overexpressed in a zebrafish model of RB1 embryonal brain tumor, and are required for neural progenitor survival and proliferation

2018 ◽  
Vol 11 (6) ◽  
pp. dmm034124 ◽  
Author(s):  
Laura E. Schultz ◽  
Jeffrey A. Haltom ◽  
Maira P. Almeida ◽  
Wesley A. Wierson ◽  
Staci L. Solin ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Neural Progenitor ◽  
Zebrafish Model ◽  
Embryonal Brain ◽  
Epigenetic Regulators ◽  
Embryonal Brain Tumor

scholarly journals Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor

2019 ◽  
Vol 146 (1) ◽  
pp. 147-156 ◽  
Author(s):  
Andrew M. Heitzer ◽  
Alexandra M. Villagran ◽  
Kimberly Raghubar ◽  
Austin L. Brown ◽  
Miranda L. Camet ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Brain Tumor ◽  
Sensorineural Hearing Loss ◽  
Adaptive Functioning ◽  
Sensorineural Hearing ◽  
Embryonal Brain ◽  
Embryonal Brain Tumor

scholarly journals Notch1 and Notch2 Have Opposite Effects on Embryonal Brain Tumor Growth

2004 ◽  
Vol 64 (21) ◽  
pp. 7787-7793 ◽  
Author(s):  
Xing Fan ◽  
Irina Mikolaenko ◽  
Ihab Elhassan ◽  
XingZhi Ni ◽  
Yunyue Wang ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Tumor Growth ◽  
Embryonal Brain ◽  
Embryonal Brain Tumor

scholarly journals Maximizing the potential of aggressive mouse tumor models in preclinical drug testing

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
M. Tarek Elghetany ◽  
Jia-Min Ho ◽  
Lois Hew Shi-Qi ◽  
Sekar Karthik ◽  
Jack M. F. Su ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Mouse Models ◽  
Drug Testing ◽  
Therapeutic Window ◽  
Tumor Models ◽  
Preclinical Testing ◽  
Narrow Therapeutic Window ◽  
Embryonal Brain ◽  
Aggressive Tumor ◽  
Embryonal Brain Tumor

AbstractAtypical teratoid rhabdoid tumor (ATRT) is an aggressive embryonal brain tumor among infants and young children. Two challenges exist for preclinical testing in ATRT. First, genetically quiet, ATRT is a difficult tumor to target molecularly. Tumor cells need to divide to propagate tumor growth—intercepting the common crossroads in cell cycle progression is a feasible strategy. KIF11 is needed for bipolar spindle formation in metaphase. We identified KIF11 as a universal target of all ATRT-molecular-subtypes. Ispinesib, a KIF11-inhibitor, effectively inhibited tumor proliferation in all seven cell lines. A second challenge—a major challenge in preclinical drug testing in-vivo among aggressive tumor models, is the narrow therapeutic window to administer drugs within the limited murine lifespan. Our most aggressive ATRT tumor model was lethal in all mice within ~ 1 month of tumor implantation. Such short-surviving mouse models are difficult to employ for preclinical drug testing due to the narrow time window to administer drugs. To overcome this time restriction, we developed a clinical staging system which allowed physically-fit mice to continue treatment, in contrast to the conventional method of fixed drug-dose-duration regimen in preclinical testing which will not be feasible in such short-surviving mouse models. We validated this approach in a second embryonal brain tumor, medulloblastoma. This is a clinically relevant, cost-efficient approach in preclinical testing for cancer and non-cancer disease phenotypes. Widely used preclinical mouse models are not the most accurate and lack the aggressive tumor spectrum found within a single tumor type. Mice bearing the most aggressive tumor spectrum progress rapidly in the limited murine life-span, resulting in a narrow therapeutic window to administer drugs, and are thus difficult to employ in preclinical testing. Our approach overcomes this challenge. We discovered ispinesib is efficacious against two embryonal brain tumor types.

Sign in / Sign up

Export Citation Format

Share Document